Key result
Astragaloside IV protects against MI by modulating anti-inflammatory, antioxidant, antifibrotic, and mitochondrial pathways.
Why the study?
Although mechanistic studies of astragaloside IV in myocardial infarction have advanced, its clinical application remains in the exploratory stage.
Astragaloside IV demonstrates multifaceted protective mechanisms against myocardial infarction in experimental models, highlighting its potential as a future therapeutic strategy pending clinical validation.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use in MI; leaves open hypothesis-generating preclinical data for randomized validation.
Myocardial infarction (MI) is a severe cardiovascular disorder characterized by an irreversible myocardial necrosis caused by acute ischemia. The typical manifestations of MI include persistent substernal chest pain, dyspnea, nausea, vomiting, and diaphoresis. Astragaloside IV (AS-IV), a major bioactive component of Astragalus membranaceus, has been extensively investigated over the past decade. Evidence indicates that AS-IV exerts multifaceted protective effects against MI by modulating various key signaling pathways involved in anti-inflammatory, anti-oxidative stress, and antifibrotic activities, the inhibition of cardiomyocyte apoptosis, and the maintenance of mitochondrial homeostasis. These pathways include TLR4/NF-[Formula: see text]B, PI3K/AKT, TGF-[Formula: see text]/Smad2, ROS/caspase-1/GSDMD, Wnt/[Formula: see text]-catenin, AMPK/ACSS2/PPAR[Formula: see text], Sirt3/Drp1, and PINK1/Parkin. Although mechanistic studies have substantially advanced, the clinical application of AS-IV in MI remains in the exploratory stage. Further well-designed clinical trials are necessary in order to validate the therapeutic efficacy and safety of AS-IV, thereby facilitating its translation from experimental research to clinical practice, and offering new insights and potential strategies for MI management.
Li et al. (2026) studied this question. Astragaloside IV protects against myocardial infarction by modulating multiple pathways related to anti-inflammation, anti-oxidation, antifibrosis, and mitochondrial homeostasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: